Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development

Journal of Virology

Volumn 88, Issue 18, 2014, Pages 10525-10540

  Nogales, Aitor ^a   Baker, Steven F ^a   Ortiz Riaño, Emilio ^a   Dewhurst, Stephen ^a   Topham, David J ^a,b   Martínez Sobrido, Luis ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; INTERFERON; NONSTRUCTURAL PROTEIN 1; NUCLEAR EXPORT PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA; CODON; INFLUENZA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CODON; CODON DEOPTIMIZATION; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; FEMALE; GENETIC PROCEDURES; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A VIRUS (A/PUERTO RICO/8/1934(H1N1)); MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROVOCATION TEST; RNA SEQUENCE; RNA SYNTHESIS; VACCINE PRODUCTION; VIROGENESIS; VIRUS ATTENUATION; VIRUS EXAMINATION; VIRUS GENE; VIRUS REPLICATION; VIRUS VIRULENCE; WILD TYPE; ANIMAL; C57BL MOUSE; GENETICS; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; INFLUENZA, HUMAN; MOLECULAR GENETICS; PROTEIN ENGINEERING; VIROLOGY;

ANIMALS; BASE SEQUENCE; CODON; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PROTEIN ENGINEERING; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84906337251     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01565-14     Document Type: Article

References (75)

1. Wright PF, Neumann G, Kawaoka Y. 2007. Orthomyxoviruses. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Strauss SE (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
2. Luckhaupt SE, Sweeney MH, Funk R, Calvert GM, Nowell M, D'Mello T, Reingold A, Meek J, Yousey-Hindes K, Arnold KE, Ryan P, Lynfield R, Morin C, Baumbach J, Zansky S, Bennett NM, Thomas A, Schaffner W, Jones T. 2012. Influenza-associated hospitalizations by industry, 2009-10 influenza season, United States. Emerg. Infect. Dis. 18:556-562. http://dx.doi.org/10.3201/eid1804.110337.
3. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. 2004. Influenza-associated hospitalizations in the United States. JAMA 292:1333-1340. http://dx.doi.org/10.1001/jama.292.11.1333.
4. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB. 2007. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25:5086-5096. http://dx.doi.org/10.1016/j.vaccine.2007.03.046.
5. Li KS, Guan Y, Wang J, Smith GJ, Xu KM, Duan L, Rahardjo AP, Puthavathana P, Buranathai C, Nguyen TD, Estoepangestie AT, Chaisingh A, Auewarakul P, Long HT, Hanh NT, Webby RJ, Poon LL, Chen H, Shortridge KF, Yuen KY, Webster RG, Peiris JS. 2004. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430:209-213. http://dx.doi.org/10.1038/nature02746.
6. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V, Okomo-Adhiambo M, Gubareva L, Barnes J, Smith CB, Emery SL, Hillman MJ, Rivailler P, Smagala J, de Graaf M, Burke DF, Fouchier RA, Pappas C, Alpuche-Aranda CM, Lopez-Gatell H, Olivera H, Lopez I, Myers CA, Faix D, Blair PJ, Yu C, Keene KM, Dotson PD, Jr, Boxrud D, Sambol AR, Abid SH, St George K, Bannerman T, Moore AL, Stringer DJ, Blevins P, Demmler-Harrison GJ, Ginsberg M, Kriner P, Waterman S, Smole S, Guevara HF, Belongia EA, Clark PA, Beatrice ST, et al. 2009. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325:197-201. http://dx.doi.org/10.1126/science.1176225.
7. Maines TR, Jayaraman A, Belser JA, Wadford DA, Pappas C, Zeng H, Gustin KM, Pearce MB, Viswanathan K, Shriver ZH, Raman R, Cox NJ, Sasisekharan R, Katz JM, Tumpey TM. 2009. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 325:484-487. http://dx.doi.org/10.1126/science.1177238.
8. Lynch JP, III, Walsh EE. 2007. Influenza: evolving strategies in treatment and prevention. Semin. Respir. Crit. Care Med. 28:144-158. http://dx.doi.org/10.1055/s-2007-976487.
9. Centers for Disease Control and Prevention. 2012. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2012-13 influenza season. MMWR Morb. Mortal. Wkly. Rep. 61:613-618. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6132a3.htm.
10. Osterholm MT, Kelley NS, Sommer A, Belongia EA. 2012. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 12:36-44. http://dx.doi.org/10.1016/S1473-3099(11)70295-X.
11. Belshe RB, Newman FK, Wilkins K, Graham IL, Babusis E, Ewell M, Frey SE. 2007. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 25:6755-6763. http://dx.doi.org/10.1016/j.vaccine.2007.06.066.
12. Centers for Disease Control and Prevention. 2010. Licensure of a highdose inactivated influenza vaccine for persons aged ≥ 65 years (Fluzone high-dose) and guidance for use-United States, 2010. MMWR Morb. Mortal. Wkly. Rep. 59:485-486. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5916a2.htm.
13. Rimmelzwaan GF, Fouchier RA, Osterhaus AD. 2007. Influenza virusspecific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr. Opin. Biotechnol. 18:529-536. http://dx.doi.org/10.1016/j.copbio.2007.11.002.
14. Cox MM, Patriarca PA, Treanor J. 2008. FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respir. Viruses 2:211-219. http://dx.doi.org/10.1111/j.1750-2659.2008.00053.x.
15. De Villiers PJ, Steele AD, Hiemstra LA, Rappaport R, Dunning AJ, Gruber WC, Forrest BD. 2009. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine 28:228-234. http://dx.doi.org/10.1016/j.vaccine.2009.09.092.
16. Lamb RA, Lai CJ. 1980. Sequence of interrupted and uninterrupted mRNAs and cloned DNA coding for the two overlapping nonstructural proteins of influenza virus. Cell 21:475-485. http://dx.doi.org/10.1016/0092-8674(80)90484-5.
17. Robb NC, Jackson D, Vreede FT, Fodor E. 2010. Splicing of influenza A virus NS1 mRNA is independent of the viral NS1 protein. J. Gen. Virol. 91:2331-2340. http://dx.doi.org/10.1099/vir.0.022004-0.
18. Garcia-Sastre A, Egorov A, Matassov D, Brandt S, Levy DE, Durbin JE, Palese P, Muster T. 1998. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252:324-330. http://dx.doi.org/10.1006/viro.1998.9508.
19. Steidle S, Martinez-Sobrido L, Mordstein M, Lienenklaus S, Garcia-Sastre A, Staheli P, Kochs G. 2010. Glycine 184 in nonstructural protein NS1 determines the virulence of influenza A virus strain PR8 without affecting the host interferon response. J. Virol. 84:12761-12770. http://dx.doi.org/10.1128/JVI.00701-10.
20. Mibayashi M, Martinez-Sobrido L, Loo YM, Cardenas WB, Gale M, Jr, Garcia-Sastre A. 2007. Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J. Virol. 81:514-524. http://dx.doi.org/10.1128/JVI.01265-06.
21. Talon J, Horvath CM, Polley R, Basler CF, Muster T, Palese P, Garcia-Sastre A. 2000. Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. J. Virol. 74:7989-7996. http://dx.doi.org/10.1128/JVI.74.17.7989-7996.2000.
22. Hale BG, Randall RE, Ortin J, Jackson D. 2008. The multifunctional NS1 protein of influenza A viruses. J. Gen. Virol. 89:2359-2376. http://dx.doi.org/10.1099/vir.0.2008/004606-0.
23. Geiss GK, Salvatore M, Tumpey TM, Carter VS, Wang X, Basler CF, Taubenberger JK, Bumgarner RE, Palese P, Katze MG, Garcia-Sastre A. 2002. Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc. Natl. Acad. Sci. U. S. A. 99:10736-10741. http://dx.doi.org/10.1073/pnas.112338099.
24. Baskin CR, Bielefeldt-Ohmann H, Garcia-Sastre A, Tumpey TM, Van Hoeven N, Carter VS, Thomas MJ, Proll S, Solorzano A, Billharz R, Fornek JL, Thomas S, Chen CH, Clark EA, Murali-Krishna K, Katze MG. 2007. Functional genomic and serological analysis of the protective immune response resulting from vaccination of macaques with an NS1-truncated influenza virus. J. Virol. 81:11817-11827. http://dx.doi.org/10.1128/JVI.00590-07.
25. Falcon AM, Fernandez-Sesma A, Nakaya Y, Moran TM, Ortin J, Garcia-Sastre A. 2005. Attenuation and immunogenicity in mice of temperature-sensitive influenza viruses expressing truncated NS1 proteins. J. Gen. Virol. 86:2817-2821. http://dx.doi.org/10.1099/vir.0.80991-0.
26. Ferko B, Stasakova J, Romanova J, Kittel C, Sereinig S, Katinger H, Egorov A. 2004. Immunogenicity and protection efficacy of replicationdeficient influenza A viruses with altered NS1 genes. J. Virol. 78:13037- 13045. http://dx.doi.org/10.1128/JVI.78.23.13037-13045.2004.
27. Solorzano A, Webby RJ, Lager KM, Janke BH, Garcia-Sastre A, Richt JA. 2005. Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. J. Virol. 79:7535- 7543. http://dx.doi.org/10.1128/JVI.79.12.7535-7543.2005.
28. Talon J, Salvatore M, O'Neill RE, Nakaya Y, Zheng H, Muster T, Garcia-Sastre A, Palese P. 2000. Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach. Proc. Natl. Acad. Sci. U. S. A. 97:4309-4314. http://dx.doi.org/10.1073/pnas.070525997.
29. Neumann G, Hughes MT, Kawaoka Y. 2000. Influenza A virus NS2 protein mediates vRNP nuclear export through NES-independent interaction with hCRM1. EMBO J. 19:6751-6758. http://dx.doi.org/10.1093/emboj/19.24.6751.
30. Bullido R, Gomez-Puertas P, Saiz MJ, Portela A. 2001. Influenza A virus NEP (NS2 protein) downregulates RNA synthesis of model template RNAs. J. Virol. 75:4912-4917. http://dx.doi.org/10.1128/JVI.75.10.4912 -4917.2001.
31. O'Neill RE, Talon J, Palese P. 1998. The influenza virus NEP (NS2 protein) mediates the nuclear export of viral ribonucleoproteins.EMBOJ. 17:288-296. http://dx.doi.org/10.1093/emboj/17.1.288.
32. Paterson D, Fodor E. 2012. Emerging roles for the influenza A virus nuclear export protein (NEP). PLoS Pathog. 8:e1003019. http://dx.doi.org/10.1371/journal.ppat.1003019.
33. Perez JT, Varble A, Sachidanandam R, Zlatev I, Manoharan M, Garcia-Sastre A, tenOever BR. 2010. Influenza A virus-generated small RNAs regulate the switch from transcription to replication. Proc. Natl. Acad. Sci. U. S. A. 107:11525-11530. http://dx.doi.org/10.1073/pnas.1001984107.
34. Guerra S, Abaitua F, Martinez-Sobrido L, Esteban M, Garcia-Sastre A, Rodriguez D. 2011. Host-range restriction of vaccinia virus E3L deletion mutant can be overcome in vitro, but not in vivo, by expression of the influenza virus NS1 protein. PLoS One 6:e28677. http://dx.doi.org/10.1371/journal.pone.0028677.
35. Hai R, Martinez-Sobrido L, Fraser KA, Ayllon J, Garcia-Sastre A, Palese P. 2008. Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach. J. Virol. 82:10580-10590. http://dx.doi.org/10.1128/JVI.01213-08.
36. Kochs G, Garcia-Sastre A, Martinez-Sobrido L. 2007. Multiple antiinterferon actions of the influenza A virus NS1 protein. J. Virol. 81:7011- 7021. http://dx.doi.org/10.1128/JVI.02581-06.
37. Kochs G, Martinez-Sobrido L, Lienenklaus S, Weiss S, Garcia-Sastre A, Staeheli P. 2009. Strong interferon-inducing capacity of a highly virulent variant of influenza A virus strain PR8 with deletions in the NS1 gene. J. Gen. Virol. 90:2990-2994. http://dx.doi.org/10.1099/vir.0.015727-0.
38. Nakamura Y, Gojobori T, Ikemura T. 2000. Codon usage tabulated from international DNA sequence databases: status for the year 2000. Nucleic Acids Res. 28:292. http://dx.doi.org/10.1093/nar/28.1.292.
39. Mueller S, Coleman JR, Papamichail D, Ward CB, Nimnual A, Futcher B, Skiena S, Wimmer E. 2010. Live attenuated influenza virus vaccines by computer-aided rational design. Nat. Biotechnol. 28:723-726. http://dx.doi.org/10.1038/nbt.1636.
40. Yang C, Skiena S, Futcher B, Mueller S, Wimmer E. 2013. Deliberate reduction of hemagglutinin and neuraminidase expression of influenza virus leads to an ultraprotective live vaccine in mice. Proc. Natl. Acad. Sci. U. S. A. 110:9481-9486. http://dx.doi.org/10.1073/pnas.1307473110.
41. Sun W. 2012. Approval letter-FluMist® quadrivalent (BL 125020/1668). U.S. Food and Drug Administration, Rockville, MD.
42. Nguyen DN, Kim P, Martinez-Sobrido L, Beitzel B, Garcia-Sastre A, Langer R, Anderson DG. 2009. A novel high-throughput cell-based method for integrated quantification of type I interferons and in vitro screening of immunostimulatory RNA drug delivery. Biotechnol. Bioeng. 103:664-675. http://dx.doi.org/10.1002/bit.22312.
43. Schickli JH, Flandorfer A, Nakaya T, Martinez-Sobrido L, Garcia-Sastre A, Palese P. 2001. Plasmid-only rescue of influenza A virus vaccine candidates. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356:1965-1973. http://dx.doi.org/10.1098/rstb.2001.0979.
44. Kilbourne ED. 1969. Future influenza vaccines and the use of genetic recombinants. Bull. World Health Organ. 41:643-645.
45. Baker SF, Guo H, Albrecht RA, Garcia-Sastre A, Topham DJ, Martinez-Sobrido L. 2013. Protection against lethal influenza with a viral mimic. J. Virol. 87:8591-8605. http://dx.doi.org/10.1128/JVI.01081-13.
46. Martinez-Sobrido L, Zuniga EI, Rosario D, Garcia-Sastre A, de la Torre JC. 2006. Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J. Virol. 80:9192-9199. http://dx.doi.org/10.1128/JVI.00555-06.
47. Park MS, Shaw ML, Munoz-Jordan J, Cros JF, Nakaya T, Bouvier N, Palese P, Garcia-Sastre A, Basler CF. 2003. Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J. Virol. 77: 1501-1511. http://dx.doi.org/10.1128/JVI.77.2.1501-1511.2003.
48. Quinlivan M, Zamarin D, Garcia-Sastre A, Cullinane A, Chambers T, Palese P. 2005. Attenuation of equine influenza viruses through truncations of the NS1 protein. J. Virol. 79:8431-8439. http://dx.doi.org/10.1128/JVI.79.13.8431-8439.2005.
49. Ozawa M, Kawaoka Y. 2011. Taming influenza viruses. Virus Res. 162: 8-11. http://dx.doi.org/10.1016/j.virusres.2011.09.035.
50. Niwa H, Yamamura K, Miyazaki J. 1991. Efficient selection for highexpression transfectants with a novel eukaryotic vector. Gene 108:193- 199. http://dx.doi.org/10.1016/0378-1119(91)90434-D.
51. Martinez-Sobrido L, Cadagan R, Steel J, Basler CF, Palese P, Moran TM, Garcia-Sastre A. 2010. Hemagglutinin-pseudotyped green fluorescent protein-expressing influenza viruses for the detection of influenza virus neutralizing antibodies. J. Virol. 84:2157-2163. http://dx.doi.org/10.1128/JVI.01433-09.
52. Martinez-Sobrido L, Garcia-Sastre A. 2010. Generation of recombinant influenza virus from plasmid DNA. J. Vis. Exp. 2010:2057. http://dx.doi.org/10.3791/2057.
53. Ortiz-Riano E, Cheng BY, de la Torre JC, Martinez-Sobrido L. 2012. Self-association of lymphocytic choriomeningitis virus nucleoprotein is mediated by its N-terminal region and is not required for its antiinterferon function. J. Virol. 86:3307-3317. http://dx.doi.org/10.1128/JVI.05503-11.
54. Donelan NR, Basler CF, Garcia-Sastre A. 2003. A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J. Virol. 77:13257- 13266. http://dx.doi.org/10.1128/JVI.77.24.13257-13266.2003.
55. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
56. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
57. Guo H, Santiago F, Lambert K, Takimoto T, Topham DJ. 2011. T cell-mediated protection against lethal 2009 pandemic H1N1 influenza virus infection in a mouse model. J. Virol. 85:448-455. http://dx.doi.org/10.1128/JVI.01812-10.
58. Steel J, Lowen AC, Pena L, Angel M, Solorzano A, Albrecht R, Perez DR, Garcia-Sastre A, Palese P. 2009. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J. Virol. 83:1742-1753. http://dx.doi.org/10.1128/JVI.01920-08.
59. Dove BK, Surtees R, Bean TJ, Munday D, Wise HM, Digard P, CarrollMW, Ajuh P, Barr JN, Hiscox JA. 2012. A quantitative proteomic analysis of lung epithelial (A549) cells infected with 2009 pandemic influenza A virus using stable isotope labelling with amino acids in cell culture. Proteomics 12:1431-1436. http://dx.doi.org/10.1002/pmic.201100470.
60. Sutejo R, Yeo DS, Myaing MZ, Hui C, Xia J, Ko D, Cheung PC, Tan BH, Sugrue RJ. 2012. Activation of type I and III interferon signalling pathways occurs in lung epithelial cells infected with low pathogenic avian influenza viruses. PLoS One 7:e33732. http://dx.doi.org/10.1371/journal.pone.0033732.
61. Chamary JV, Hurst LD. 2005. Evidence for selection on synonymous mutations affecting stability of mRNA secondary structure in mammals. Genome Biol. 6:R75. http://dx.doi.org/10.1186/gb-2005-6-9-r75.
62. Kanaya S, Yamada Y, Kinouchi M, Kudo Y, Ikemura T. 2001. Codon usage and tRNA genes in eukaryotes: correlation of codon usage diversity with translation efficiency and with CG-dinucleotide usage as assessed by multivariate analysis. J. Mol. Evol. 53:290-298. http://dx.doi.org/10.1007/s002390010219.
63. Lavner Y, Kotlar D. 2005. Codon bias as a factor in regulating expression via translation rate in the human genome. Gene 345:127-138. http://dx.doi.org/10.1016/j.gene.2004.11.035.
64. Gustafsson C, Govindarajan S, Minshull J. 2004. Codon bias and heterologous protein expression. Trends Biotechnol. 22:346-353. http://dx.doi.org/10.1016/j.tibtech.2004.04.006.
65. Kozak M. 2002. Pushing the limits of the scanning mechanism for initiation of translation. Gene 299:1-34. http://dx.doi.org/10.1016/S0378 -1119(02)01056-9.
66. Shabalina SA, Ogurtsov AY, Spiridonov NA. 2006. A periodic pattern of mRNAsecondary structure created by the genetic code. Nucleic Acids Res. 34:2428-2437. http://dx.doi.org/10.1093/nar/gkl287.
67. Garaigorta U, Ortin J. 2007. Mutation analysis of a recombinant NS replicon shows that influenza virus NS1 protein blocks the splicing and nucleo-cytoplasmic transport of its own viral mRNA. Nucleic Acids Res. 35:4573-4582. http://dx.doi.org/10.1093/nar/gkm230.
68. Chua MA, Schmid S, Perez JT, Langlois RA, Tenoever BR. 2013. Influenza A virus utilizes suboptimal splicing to coordinate the timing of infection. Cell Rep. 3:23-29. http://dx.doi.org/10.1016/j.celrep.2012.12.010.
69. Randall RE, Goodbourn S. 2008. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol. 89:1-47. http://dx.doi.org/10.1099/vir.0.83391-0.
70. Hussain AI, Cordeiro M, Sevilla E, Liu J. 2010. Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells. Vaccine 28:3848-3855. http://dx.doi.org/10.1016/j.vaccine.2010.03.005.
71. Pica N, Palese P. 2013. Toward a universal influenza virus vaccine: prospects and challenges. Annu. Rev. Med. 64:189-202. http://dx.doi.org/10.1146/annurev-med-120611-145115.
72. Richt JA, Lekcharoensuk P, Lager KM, Vincent AL, Loiacono CM, Janke BH, Wu WH, Yoon KJ, Webby RJ, Solorzano A, Garcia-Sastre A. 2006. Vaccination of pigs against swine influenza viruses by using an NS1-truncated modified live-virus vaccine. J. Virol. 80:11009-11018. http://dx.doi.org/10.1128/JVI.00787-06.
73. Vincent AL, Ma W, Lager KM, Janke BH, Webby RJ, Garcia-Sastre A, Richt JA. 2007. Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. Vaccine 25:7999-8009. http://dx.doi.org/10.1016/j.vaccine.2007.09.019.
74. Wimmer E, Mueller S, Tumpey TM, Taubenberger JK. 2009. Synthetic viruses: a new opportunity to understand and prevent viral disease. Nat. Biotechnol. 27:1163-1172. http://dx.doi.org/10.1038/nbt.1593.
75. Versteeg GA, Garcia-Sastre A. 2010. Viral tricks to grid-lock the type I interferon system. Curr. Opin. Microbiol. 13:508-516. http://dx.doi.org /10.1016/j.mib.2010.05.009.